IgG antibody subclasses, tumor necrosis factor and IFN-γ levels in patients with type II lepra reaction on thalidomide treatment

International Archives of Allergy and Immunology

Volumn 116, Issue 1, 1998, Pages 60-66

  Partiada Sanchez, S ^a   Favila Castillo, L ^a   Pedraza Sanchez, S ^a   Gomez Melgar, M ^b   Saul, A ^b   Estrada Parra, S ^a   Estrada Garcia, I ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b SECRETARÍA DE SALUD   (Mexico)

Author keywords

Cytokines; IgG subclasses; Interferon ; Lepra reaction; Thalidomide; Tumor necrosis factor

Indexed keywords

CLOFAZIMINE; DAPSONE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; PREDNISONE; RIFAMPICIN; THALIDOMIDE; TUMOR NECROSIS FACTOR;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHEMA NODOSUM LEPROSUM; HUMAN; MYCOBACTERIUM LEPRAE; NONHUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; DATA INTERPRETATION, STATISTICAL; ERYTHEMA NODOSUM; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON TYPE II; LEPROSTATIC AGENTS; LEPROSY, BORDERLINE; LEPROSY, LEPROMATOUS; LEPROSY, TUBERCULOID; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031947779     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000023926     Document Type: Article

References (25)

1. Ridley DS, Jopling WH: Classification of leprosy according to immunity. A five group system. Int J Lepr Other Mycobact Dis 1966;34: 255-273.
2. Bloom BR, Mehra V: Immunological unresponsiveness in leprosy. Immunol Rev 1984;80: 5-28.
3. Wemambu SNC, Turk JL, Waters MFR, Rees RJW: Erythema nodosum leprosum: A clinical manifestation of Arthus phenomenom. Lancet 1969;ii:933-935.
4. Rojas-Espinoza O, Mendez-Navarrete I, Estrada-Parra S: Presence of C1q reactive immune complexes in patients with leprosy. Clin Exp Immunol 1972;12:215-223.
5. Bjorvatn B, Barneston RCS, Kronval G, et al: Immune complexes and complement hypercatabolism in patients with leprosy. Clin Exp Immunol 1976;26:388-396.
6. Laal S, Bhutani LK, Nath I: Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum. Infect Immun 1985;50:887-892.
7. Modlin RL, Mehra V, Jordan R, Bloom BR, Rea TH: In situ and in vitro characterization of the cellular immune response in erythema nodosum leprosum. J Immunol 1986;136:883-886.
8. Sarno EN, Grau GE, Vieira LMM, Nery JA: Serum levels of tumor necrosis factor-alpha and interleukin-1β during leprosy reactional states. Clin Exp Immunol 1991;84:103-108.
9. Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303-306.
10. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173: 699-703.
11. Bermudez LEM, Young LJ: Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988;140:3006-3013.
12. Kindler V, Sappino A-P, Grau GE, Piguet P-F, Vassali P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56: 731-740.
13. Selmaj KW, Raine CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-346.
14. Grau GE, Piguet P-H, Vasalli P, et al: Involvement of tumor necrosis factor and other cytokines in immune mediated vascular pathology. Int Arch Allergy Appl Immunol 1989;88:34-37.
15. Matthews N, Neale ML: Cytotoxicity assays for tumour necrosis factor and lymphotoxin; in Clemens MJ, Morris AG, Gearing AJH (eds): Lymphokines and Interferons. Oxford, IRL Press, 1987, pp 221-225.
16. Favre C, Cabrillat WH, Djossou O, Banchereau J, De Vries JE: Epitope mapping of recombinant human gamma interferon using monoclonal antibodies. Mol Immunol 1989;26:17-25.
17. Abrams JS, Roncarolo M-J, Yssel H, Andersson U, Gleich GH, Silver JE: Strategies of anticytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 1992;127:5-24.
18. Dhandayuthapani S, Izumi S, Anandan D, Bathia VN: Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Clin Exp Immunol 1992;88:253-257.
19. Kifayet A, Hussain R: Selective decrease of M. leprae specific IgG1 and IgG3 antibodies in leprosy patients associated with ENL. Int J Lepr Other Mycobact Dis 1996;64:105-114.
20. Barnes PF, Chatterjee D, Brennan, PJ Rea TH, Modlin RL: Tumor necrosis factor production in patients with leprosy. Infect Immun 1992;60: 1441-1446.
21. Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel CP, Viana SM, Sarno EN: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-44.
22. Kaplan G, Cohn ZA: The immunobiology of leprosy. Int Rev Exp Pathol 1986;28:45-53.
23. Bancroft GJ: The role of natural killer cells in innate resistance to infection. Curr Opin Immunol 1993;5:503-510.
24. Hass W, Pereira P, Tonegawa S: Gamma/delta cells. Annu Rev Immunol 1993;11:637-685.
25. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G: Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous patients. J Exp Med 1992;715:1729-1737.